Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation

Eur Heart J. 2014 Oct 7;35(38):2639-54. doi: 10.1093/eurheartj/ehu257. Epub 2014 Jul 25.

Abstract

This article provides an overview on procedure-related issues and uncertainties in outcomes after transcatheter aortic valve implantation (TAVI). The different access sites and how to select them in an individual patient are discussed. Also, the occurrence and potential predictors of aortic regurgitation (AR) after TAVI are addressed. The different methods to quantify AR are reviewed, and it appears that accurate and reproducible quantification is suboptimal. Complications such as prosthesis-patient mismatch and conduction abnormalities (and need for permanent pacemaker) are discussed, as well as cerebrovascular events, which emphasize the development of optimal anti-coagulative strategies. Finally, recent registries have shown the adoption of TAVI in the real world, but longer follow-up studies are needed to evaluate the outcome (but also prosthesis durability). Additionally, future studies are briefly discussed, which will address the use of TAVI in pure AR and lower-risk patients.

Keywords: Access site; Aortic regurgitation; Complications; Registries; Transcatheter aortic valve implantation.

Publication types

  • Review

MeSH terms

  • Aortic Valve Insufficiency / etiology
  • Aortic Valve Insufficiency / prevention & control
  • Aortic Valve Stenosis / surgery*
  • Arrhythmias, Cardiac / etiology
  • Arrhythmias, Cardiac / therapy
  • Bioprosthesis
  • Cardiac Imaging Techniques
  • Fibrinolytic Agents / therapeutic use
  • Forecasting
  • Humans
  • Pacemaker, Artificial
  • Patient Selection
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Prognosis
  • Prosthesis Failure
  • Stroke / etiology
  • Stroke / prevention & control
  • Transcatheter Aortic Valve Replacement / methods*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents